Could COX-2 Inhibition With Celecoxib Have Role in Breast Cancer?

In this video, R. Charles Coombes, MD, PhD, of Imperial College London, United Kingdom, discusses results of REACT (Randomised European Celecoxib Trial), a phase III multi-center double-blind randomized trial of celecoxib vs placebo in patients with breast cancer.

Coombes presented results of this study (abstract GS3-03) at the 2017 San Antonio Breast Cancer Symposium (SABCS).